Table 1.
Summary of the Clinical Features
| Characteristics | Total Primary (n = 48) | IDH Mutant (n = 19) | IDH Wild Type (n = 7) | IDH Unknown (n = 22) |
|---|---|---|---|---|
| Clinical | ||||
| Anaplastic astrocytoma | 6 (12.5%) | 3 (15.8%) | 2 (28.6%) | 1 (4.5%) |
| Anaplastic oligodendroglioma | 5 (10.4%) | 3 (15.8%) | 2 (28.6%) | 0 (0%) |
| Glioblastoma | 27 (56.3%) | 3 (15.8%) | 3 (42.8%) | 21 (95.5%) |
| Astrocytoma | 5 (10.4%) | 5 (26.3%) | 0 (0%) | 0 (0%) |
| Oligodendroglioma | 5 (10.4%) | 5 (26.3%) | 0 (0%) | 0 (0%) |
| Age | ||||
| Mean (SD) | 54.5 ± 15.7 | 47.8 ± 17.2 | 59.7 ± 20.4 | 58.6 ± 10.6 |
| Range | 21-82 | 28-78 | 21-79 | 44-82 |
| Race | ||||
| Black or African American | 8 (16.7%) | 3 (15.8%) | 3 (42.9%) | 2 (9.1%) |
| Caucasian | 38 (79.1%) | 14 (73.6%) | 4 (57.1%) | 20 (90.9%) |
| Hispanic | 1 (2.1%) | 1 (5.3%) | 0 (0%) | 0 (0%) |
| Indian | 1 (2.1%) | 1 (5.3%) | 0 (0%) | 0 (0%) |
| Survival | ||||
| Mean (LQ-UQ) (months) | 38 (20.1-55.7) | 50.4 (40.9-65.6) | 27.1 (8.9-33.7) | 30.8 (18.1-37.4) |
| Gender | ||||
| Female | 17 (35.4%) | 9 (47.4%) | 5 (71.4%) | 3 (13.6%) |
| Male | 31 (64.6%) | 10 (52.6%) | 2 (28.6%) | 19 (86.4%) |
| 1p19q Codel status | ||||
| Intact | 24 (50.0%) | 10 (52.6%) | 7 (100%) | 7 (31.8%) |
| Co-deleted | 9 (18.8%) | 7 (36.9%) | 0 (0%) | 2 (9.1%) |
| Unknown | 15 (31.2%) | 2 (10.5%) | 0 (0%) | 13 (59.1%) |
| MGMT promoter status | ||||
| Methylated | 27 (56.2%) | 15 (78.9%) | 4 (57.1%) | 8 (36.4%) |
| Unmethylated | 21 (43.8%) | 4 (21.1%) | 3 (42.9%) | 14 (63.6%) |
Abbreviations: LQ-UQ, lower quartiles-upper quartiles; MGMT, O-6-methylguanine-DNA methyltransferase.